[{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Resveratrol","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jupiter Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"","sponsorNew":"Jupiter Neurosciences \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Jupiter Neurosciences \/ Spartan Capital Securities"}]

Find Clinical Drug Pipeline Developments & Deals for Resveratrol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Jupiter Neurosciences is developing JNS101 (resveratrol) is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions.

                          Brand Name : Jotrol

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 02, 2022

                          Lead Product(s) : Resveratrol

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Spartan Capital Securities

                          Deal Size : $15.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : The U.S. patent covers the suspension of active ingredient resveratrol and other compounds in a micellar emulsion that can be delivered via oral capsule.

                          Brand Name : Jotrol

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 01, 2020

                          Lead Product(s) : Resveratrol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : The company's lead candidate, IMC-1, is a novel combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral mediated disease burden.

                          Brand Name : Jotrol

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 22, 2020

                          Lead Product(s) : Resveratrol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : National Institutes of Health

                          Deal Size : $1.7 million

                          Deal Type : Funding

                          blank